1 Title

- 2 Monitoring transmission intensity of trachoma with serology
- 3

4 Author List

- 5 Christine Tedijanto¹, Anthony W. Solomon², Diana L. Martin³, Scott D. Nash⁴, Jeremy D.
- 6 Keenan^{1,5}, Thomas M. Lietman^{1,5,6,7}, Patrick J. Lammie⁸, Kristen Aiemjoy⁹, Abdou Amza^{10,11},
- 7 Solomon Aragie^{1,12,13}, Ahmed M. Arzika¹⁴, E. Kelly Callahan⁴, Sydney Carolan¹, Adisu Abebe
- ⁸ Dawed¹⁵, E. Brook Goodhew³, Sarah Gwyn³, Jaouad Hammou¹⁶, Boubacar Kadri^{10,11},
- 9 Khumbo Kalua¹⁷, Ramatou Maliki¹⁴, Beido Nassirou^{10,11}, Fikre Seife¹⁸, Zerihun Tadesse¹²,
- 10 Sheila K. West¹⁹, Dionna M. Wittberg¹, Taye Zeru²⁰, Benjamin F. Arnold^{1,5}*
- 11
- 12 * Corresponding Author:
- 13 Benjamin F. Arnold, PhD
- 14 Associate Professor
- 15 F.I. Proctor Foundation
- 16 University of California, San Francisco
- 17 <u>ben.arnold@ucsf.edu</u>
- 18

19 Affiliations

- ²⁰ ¹ Francis I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA,
- 21 94158
- ² Global Neglected Tropical Diseases Programme, World Health Organization, Geneva, Switzerland
- ³ Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA,
 USA 30329
- ⁴ The Carter Center, Atlanta, GA, USA, 30307
- ⁵ Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA,
 94158
- ⁶ Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA
 94143
- ³⁰ ⁷ Department of Epidemiology and Biostatistics, University of California San Francisco, San
- 31 Francisco, CA 94143
- ⁸Neglected Tropical Diseases Support Center, Task Force for Global Health, Atlanta, GA, USA,
- 33 30030
- ⁹ Division of Epidemiology, Department of Public Health Sciences, University of California Davis
- 35 School of Medicine, Davis, CA, USA
- 36 ¹⁰ Programme National de Santé Oculaire, Niamey, Niger
- 37 ¹¹ Programme National de Lutte Contre la Cecité, Niamey, Niger
- 38 ¹² The Carter Center Ethiopia, Addis Ababa, Ethiopia
- ³⁹ ¹³ Infection Biology, Addis Ababa University, Addis Ababa, Ethiopia
- 40 ¹⁴ The Carter Center Niger, Niamey, Niger
- 41 ¹⁵ Amhara Regional Health Bureau, Bahir-Dar, Ethiopia
- 42 ¹⁶ Service of Ocular and Otological Diseases, Epidemiology and Disease Control Directorate, Ministry
- 43 of Health, Morocco
- 44 ¹⁷ Blantyre Institute for Community Outreach, Malawi
- 45 ¹⁸ Federal Ministry of Health, Addis Ababa, Ethiopia
- ⁴⁶ ¹⁹ Johns Hopkins School of Medicine, Dana Center for Preventive Ophthalmology, Wilmer Eye
- 47 Institute, Baltimore MD USA
- 48 ²⁰ Amhara Public Health Institute, Bahir-Dar, Ethiopia

49 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

50 Abstract

51

52 Trachoma, caused by ocular *Chlamydia trachomatis* infection, is targeted for global

- elimination as a public health problem by 2030. To provide evidence for use of
- ⁵⁴ antibodies to monitor *C. trachomatis* transmission, we collated IgG responses to
- ⁵⁵ Pgp3 antigen, PCR positivity, and clinical observations from 19,811 children aged 1–
- 56 9 years in 14 populations. We demonstrate that age-seroprevalence curves
- 57 consistently shift along a gradient of transmission intensity: rising steeply in
- 58 populations with high levels of infection and active trachoma and becoming flat in
- 59 populations near elimination. Seroprevalence (range: 0–54%) and seroconversion
- rates (range: 0–15 per 100 person-years) correlate with PCR prevalence (r: 0.87,
- 95% CI: 0.57, 0.97). A seroprevalence threshold of 13.5% (seroconversion rate 2.75
- 62 per 100 person-years) identifies clusters with any PCR-identified infection at high
- 63 sensitivity (>90%) and moderate specificity (69-75%). Antibody responses in young
- 64 children provide a robust, generalizable approach to monitor population progress
- 65 toward and beyond trachoma elimination.

67 Introduction

Trachoma is the leading infectious cause of blindness and has been targeted for 68 elimination as a public health problem by 2030.¹ Caused by repeated infections with 69 the bacterium Chlamydia trachomatis, trachoma has historically been monitored via 70 district-level estimates of clinical signs.² However, clinical signs may not align well 71 with transmission intensity, particularly after mass drug administration of 72 azithromycin (MDA)³⁻⁵, and are prone to measurement error, especially as cases 73 become rare.⁶⁻⁸ As a result, there has been growing interest in IgG antibody 74 responses as an objective and easy-to-collect biomarker to inform control programs. 75 Based on examples from other infectious diseases including malaria⁹ and SARS-76 CoV-2,¹⁰ use cases for trachoma serology may include monitoring population-level 77 78 transmission to determine appropriate interventions, post-validation surveillance, opportunistic investigation of populations using blood collected for other purposes, 79 and fine-scale geographic targeting of control measures.^{11–13} 80

81

IgG antibody responses to *C. trachomatis* antigens Pgp3 and CT694 are sensitive
and specific markers of *C. trachomatis* infection.^{14,15} Assays have demonstrated
consistency across platforms (multiplex bead, enzyme-linked immunosorbent, lateral
flow),¹⁶⁻¹⁸ robust seropositivity cutoffs.¹⁹ and high repeatability.^{18,20} Of the two

flow),^{16–18} robust seropositivity cutoffs,¹⁹ and high repeatability.^{18,20} Of the two
 antigens, Pgp3 appears to elicit a stronger and more durable response and is

collected in most trachoma serology surveys.²¹ In epidemiologic studies,

investigators have observed alignment between population-level summaries of

antibody response and other trachoma markers, including the presence of *C*.

90 trachomatis DNA, as determined by PCR, and the active trachoma sign

91 trachomatous inflammation—follicular (TF). Individual studies suggest age-

92 dependent seroprevalence curves rise steeply with age among children in trachoma-

93 endemic communities ^{14,15} and are flat in communities that have eliminated

 94 trachoma.^{22–24} IgG responses to Pgp3 can be measured from dried blood spots and

95 have the potential to be scaled through integration in multiplex surveillance

⁹⁶ strategies with other infectious pathogens.²⁵ Key next steps to advance the use of

97 serology to monitor trachoma programs are to benchmark serology against

independent measures of transmission, notably PCR, and to formalize the analytic
 approaches used to summarize trachoma antibody data.

100

Here, we collated IgG antibody, infection, and clinical data from 14 populations in 101 five countries across a gradient of trachoma transmission intensities that ranged 102 from hyper-endemic to post-elimination. Due to the shortcomings of clinical signs, we 103 used PCR as the primary marker of trachoma activity, with TF as a secondary 104 indicator to contextualize serologic estimates. We hypothesized that population-level 105 summaries of trachoma antibody measurements would follow a consistent path 106 toward elimination, characterized by flattening of age-seroprevalence curves and a 107 corresponding decline in seroconversion rates. We also hypothesized that different 108 seroepidemiologic summary measures (e.g. seroprevalence, seroconversion rates) 109

- 110 would be consistent with one another and align similarly with population-level
- transmission. We completed a series of analyses to test these hypotheses and in
- doing so, develop robust analytic methods for trachoma serology as we approach
- the elimination endgame.
- 114

115 **Results**

116 Study populations and settings

We combined serologic, molecular, and clinical measurements collected between 117 2012 and 2019 across nine studies in five countries (Supplementary Table 1).²⁶⁻³⁸ 118 When possible, measurements within the same study were stratified into populations 119 corresponding to trachoma evaluation units, resulting in 14 study populations. All 120 121 studies were conducted in Africa and represented a gradient of trachoma transmission from hyper-endemic transmission to post-elimination. Measurements 122 were taken at a single time point or in repeated cross-sectional visits (typically 123 annual measurements). Due to changing transmission and/or interventions over time 124 in some studies, analyses included only the most recent round of measurements for 125 each population. We analyzed sampling clusters with 15 or more serologic 126 measurements, a total of 459 clusters. The median number of children contributing 127 information per cluster was 40 (interguartile range: 32–47) (Supplementary Fig. 1), 128 for a total of 19,811 serologic measurements. Eleven studies included children aged 129 1–9 years, and three studies focused on children aged 1–5 years (Supplementary 130 Fig. 2).

131 132

133 We generated population-level summaries using the median and range across

134 clusters and observed wide variation in seroprevalence (median: 8%; range: 0–

135 54%), PCR prevalence (median: 3%; range: 0–26%), and TF prevalence (median:

6%; range: 0–56%) (Fig. 1). PCR, a measure of current infection, may disappear
 rapidly following MDA ³⁹. Among clusters with MDA in the past year, the median PCR

prevalence was 0%, while among clusters without recent MDA, PCR prevalence was

139 12%. Cluster-level estimates within the same population were often variable, likely a

- 140 combination of heterogeneity in disease transmission and stochasticity due to
- smaller sample sizes. Across the gradient of transmission intensities, population-

level summaries of seroprevalence aligned with PCR and TF prevalence (**Fig. 1**).

143

144 Charting progress toward elimination with serology

We estimated age-dependent seroprevalence curves using semiparametric splines 145 and seroconversion rates from age-structured seroprevalence (Methods). Across 146 147 populations, seroconversion rates ranged from 0 to 15 per 100 person-years (median: 1.7) using a catalytic model without seroreversion (Fig. 2). Consistent with 148 our hypothesis, we observed that age-seroprevalence curves were flatter and 149 seroconversion rates were lower in areas with lower PCR prevalence. Age-150 seroprevalence curves rose steeply in settings with high levels of infection such as 151 Wag Hemra and Andabet, Ethiopia, reaching >50% seroprevalence by age 9 years. 152

In contrast, in populations with flatter curves (<10% seroprevalence by age 9 years,
 seroconversion rate <1 per 100 person-years), PCR prevalence was 0% when
 measured (Woreta town and Alefa, Ethiopia). Among populations with moderately

- 156 increasing age-seroprevalence curves, roughly corresponding to seroconversion
- 157 rates between 1 and 5 per 100 person-years, PCR prevalence ranged from 0 (Dera,
- 158 Ethiopia) to 1.9% (Kongwa, Tanzania 2018).
- 159

160 Agreement between serology-based summary measures

Summary statistics estimated from age-seroprevalence curves provide additional, 161 useful summary measures of transmission.^{9,40} Population-level summaries of IgG 162 responses include geometric mean IgG levels, seroprevalence, and seroconversion 163 rates — each progression from IgG levels to seroconversion rates relies on 164 additional model assumptions and analysis complexity (details in Methods). In the 165 estimation of seroconversion rates from age-structured seroprevalence, we 166 considered a range of model complexity that included a catalytic model 167 (corresponding to a susceptible-infected-recovered, SIR, model), a reversible 168 catalytic model allowing for seroreversion (corresponding to a susceptible-infected-169 170 susceptible, SIS, model), and a semiparametric hazard model that allowed for age-

- 171 varying seroconversion rates.
- 172

A key question for elimination programs is whether the additional complexity in 173 analysis leads to more useful information for identifying populations with ongoing 174 ocular C. trachomatis transmission. We estimated each summary at the sampling 175 cluster and population levels across the 14 study populations and found high 176 correlation between all measures (Spearman $\rho \ge 0.88$ for all comparisons, Fig. 3). 177 Cluster-level seroprevalence was strongly, linearly related with geometric mean IgG 178 levels on the log₁₀ scale (Fig. 3a), and there was a strong, non-linear relationship 179 between seroprevalence and the seroconversion rate (Fig. 3b). Catalytic models 180 that allowed for seroreversion shifted seroconversion rates up, particularly for 181 clusters with a seroconversion rate greater than 20 per 100 person-years but had 182 183 minimal influence on estimates at intermediate and lower levels of transmission (Fig. 3c). Similarly, seroprevalence was tightly linked with seroconversion rates that 184 allowed for seroreversion in settings with lower prevalence, and greater dispersion 185 was observed in hyperendemic populations (Fig. 3d). The most complex model, a 186 semiparametric proportional hazards spline model that allowed for an age-varying 187 seroconversion rate, required more data than would be typically available at the 188 sampling cluster level and thus could only be estimated at the population level where 189 its estimates aligned closely with a simpler, constant rate model (Supplementary 190 Fig. 3). These results show that all serologic summary measures provide similar 191 information when averaged at the cluster or population level across all ranges of 192 193 transmission and particularly at lower levels of transmission. 194 Comparing trachoma indicators in the presence and absence of MDA 195

As most trachoma program interventions act to clear infection or reduce its 196 transmission, we sought summaries that could capture variation in populations' C. 197 trachomatis infection burden. Seroprevalence and PCR prevalence aligned closely 198 at the population level (r = 0.87; 95% CI: 0.57–0.97, Fig. 4a). At both the cluster- and 199 population-levels, seroprevalence was almost always greater than or equal to PCR 200 prevalence, underscoring the sensitivity of seroprevalence as a measure of current 201 or past infection. However, PCR prevalence was highly variable across levels of 202 seroprevalence; low PCR prevalence in the context of high seroprevalence may 203 imply previously high levels of infection that had been controlled by MDA or other 204 interventions. Relationships between TF and PCR prevalence were similar 205 (population-level *r* = 0.92; 95% CI: 0.70–0.98, **Fig. 4b**). 206

207

As shown in prior work,⁴¹ TF and seroprevalence were more strongly correlated with PCR prevalence in the absence of MDA in the past year (**Fig. 4a, 4b**). In the absence of MDA, the relationship between seroprevalence and PCR prevalence was nearly linear, particularly in high transmission settings. In the presence of recent MDA, correlations between trachoma indicators weakened presumably because IgG and TF prevalence remain elevated as durable indicators of trachoma even after infections have been reduced through MDA.

215

We also stratified the analyses by child age and observed similar correlations 216 between indicators among children aged 1–9 years compared to children aged 1–5 217 years (Fig. 5). When summarizing IgG responses as seroconversion rate instead of 218 seroprevalence, overall results and subgroup results by recent MDA and age group 219 were similar (Supplementary Fig. 4), reflecting the tight correlation between 220 serologic summaries (Fig. 3). Our results show that serologic summaries align with 221 PCR prevalence as well or better than TF, the current programmatic indicator, and 222 that serology performs well even among preschool aged children. In populations that 223 have recently undergone MDA, IgG and TF will likely remain elevated even as 224 infection prevalence falls. 225

226

227 Assessing serologic thresholds for elimination of infections

Due to the wide variability in trachoma indicators both within and between 228 populations, we used a nonparametric approach to evaluate potential serologic 229 summary thresholds. Based on the alignment between seroprevalence and PCR at 230 the cluster level and the relatively large number of clusters, we assessed sensitivity 231 and specificity using cluster-level values. At each potential threshold, sensitivity and 232 specificity were calculated across the 281 clusters with PCR measurements, 112 of 233 234 which had at least one infection detected by PCR. Although presence of a single infection is a stringent threshold, an appropriate level of PCR prevalence required to 235 prevent blindness due to trachoma has yet to be established. Under this definition, a 236 threshold with high sensitivity would result in more infected clusters being detected, 237 while a threshold with high specificity might imply less unnecessary intervention. 238

239 While overtreatment should be avoided, we focused on thresholds with high 240 sensitivity with the goal of elimination in mind.

241

There was good classification of clusters with and without *C. trachomatis* infections 242 based on either seroprevalence or seroconversion rates (AUC=0.92). Thresholds of 243 13.5% seroprevalence (Fig. 6) or 2.75 seroconversions per 100 person-years 244 (Supplementary Fig. 5) had 90% sensitivity and 69-75% specificity to identify 245 clusters with any PCR-detected infections. Thresholds of 22.5% seroprevalence and 246 5.75 seroconversions per 100 person-years had 80% sensitivity and 92-93% 247 specificity. Thresholds were conservative when compared against population-248 specific sensitivity estimates in high transmission settings, but sensitivity dropped 249 quickly in lower transmission populations with few infected clusters (n=4 in 250 Chikwawa, Malawi and n=6 in Mchinji, Malawi) (Fig. 6a). 251

252

In a sensitivity analysis we repeated the approach including only children aged 1–5
years, since restricting to younger ages should result in overall lower seroprevalence
and potentially different seroconversion rates. We found classification of clusters
with and without *C. trachomatis* infections was almost identical to the main analysis
(AUC=0.92), and thresholds of 12.5% seroprevalence and 2.75 conversions per 100
person-years had 90% sensitivity and 69-71% specificity to identify clusters with any
PCR-detected infections (**Supplementary Fig 6**).

260

In a supplementary assessment of the thresholds, we applied them to populations 261 with very low trachoma prevalence that were not included in the threshold analysis 262 because cluster-level PCR results were unavailable (Dosso, Alefa, and Woreta town, 263 see Figs. 1 and 2). District-level PCR from Alefa and Woreta town, Ethiopia were 264 estimated to be 0%, and a recent study from the same population in Dosso, Niger 265 found no *C. trachomatis* in pooled metagenomic testing of ocular swabs.³⁸ In these 266 three populations, 98% of clusters (60/61) fell below the serologic thresholds for 90% 267 sensitivity, supporting the interpretation of low levels of infection below the estimated 268 269 thresholds.

270

271 Discussion

Using antibody measurements from 14 populations across a gradient of *C*.

- 273 trachomatis transmission intensity, we demonstrated that IgG Pgp3 age-
- 274 seroprevalence curves flatten and seroprevalence and seroconversion rates
- 275 progress toward zero as populations approach elimination, consistent with biological
- assumptions and observations across other pathogens.^{40,42} To our knowledge, this is
- 277 the largest synthesis of *C. trachomatis* serology and infection data spanning globally
- 278 relevant transmission settings from hyper-endemic to elimination. Summaries of IgG
- responses to *C. trachomatis* antigen Pgp3 among children aged 1–9 years aligned
- similarly with PCR prevalence and with one another at both the cluster- and
- population-levels, indicating that cluster-level Pgp3 summaries reflect variation in *C*.

trachomatis infections and ongoing transmission. Combining information across all
populations, we found that thresholds of 13.5% seroprevalence and 2.75
seroconversions per 100 person-years identified clusters with any infection with high
sensitivity (>90%) and moderate specificity (69 to 75%). We observed similar results
when analyses were restricted to children aged 1–5 years, an age group that is
potentially easier to sample in household surveys as they are not yet in school.

We demonstrated that seroprevalence and seroconversion rates perform as well or 289 better as correlates of population levels of infection compared with clinical TF, and 290 serology is arguably more objective, granular, and scalable for surveillance. 291 Although clinical signs are important markers of disease progression, MDA is 292 targeted towards C. trachomatis infections — if clinical signs continue to be present 293 in the absence of antibody responses, further investigation may be warranted to 294 determine other potential causes of inflammation. Compared to PCR, which also 295 measures C. trachomatis infections, serology is cost-effective, with simpler collection 296 procedures and the opportunity to leverage banked samples, and measures 297 exposure over time versus at a single point, an advantage in low prevalence 298 299 settings.

300

By focusing on parsimonious, generalizable methods, our aim was to present 301 seroepidemiologic approaches that could be easily applied and interpreted by 302 trachoma control programs. Trachoma programs currently rely on district-level 303 estimates of active trachoma, and this analysis may be extended to develop district-304 level thresholds as an increasing number of district-level, population-based serologic 305 surveys become available. Cluster-level estimates, as investigated here, may be a 306 promising alternative to identify focal areas for intervention, particularly in 307 combination with geostatistical methods to improve precision and project across 308 unsurveyed regions.43 309

310

Programmatic decisions related to suspension or reinitiation of antibiotic MDA 311 312 primarily take place in low to intermediate transmission settings, and this study demonstrates that the information serologic surveillance provides in such settings 313 should be robust to choice of summary statistic. Serologic summaries of increasing 314 complexity were tightly correlated with one another, and the relationship was nearly 315 linear in settings with low to intermediate transmission (Fig. 3). Quantitative IgG 316 responses potentially provide information at very low levels of C. trachomatis 317 transmission when most children are seronegative,⁴⁴ but a challenge is that IgG 318 responses are in arbitrary units that may not be directly comparable across studies. 319 320 Members of our team recently developed a chimeric, monoclonal antibody to help facilitate direct comparison of quantitative antibody levels across studies.¹⁸ 321 Seroprevalence and seroconversion rates are standard transformations of the 322 quantitative IgG response that are easier to compare across studies and labs. A 323 potential drawback of seroprevalence and seroconversion is that they may be 324 325 sensitive to choice of the seropositivity cutoff, potentially affecting programmatic

decisions based on thresholds. In a sensitivity analysis, we found that identification 326 of clusters with C. trachomatis infection based on seroprevalence and 327 seroconversion rates were robust to large changes in the seropositivity cutoff 328 (Supplementary Fig 7). The seroconversion rate is tightly linked to the slope of the 329 age-seroprevalence curve (details in Methods). Additionally, the seroconversion rate 330 implicitly adjusts for age (not guaranteed with mean IgG or seroprevalence) and can 331 be interpreted as a measure of a pathogen's force of infection. Although we did not 332 consider complicated seroconversion models that allowed for changes in 333 334 transmission over time, such complexity may be less relevant when analyzing measurements from young children because their antibody responses reflect recent 335 infections.45-47 336

337

Our results support estimation of age-seroprevalence curves among young children 338 combined with estimation of seroconversion rates using a simple, single-rate model 339 to characterize trachoma transmission. Our findings demonstrate that the slope of 340 the age-seroprevalence curve and the seroconversion rate are sensitive and 341 moderately specific markers of population-level C. trachomatis infection. 342 Seroprevalence is another simple, robust summary measure that aligned with 343 infections as well as seroconversion rate, particularly in the absence of recent MDA, 344 but care should be taken to ensure similar age structure between populations to 345 avoid bias.

346 347

We found that serologic summaries were sensitive indicators of C. trachomatis 348 infection but have only moderate specificity: antibody responses were nearly always 349 present in populations with infections, but the IgG signal persisted even if recent 350 MDA reduced infection to low levels. This pattern suggests that populations requiring 351 treatment will rarely be missed by serology but further verification with PCR could 352 prevent overtreatment in the case of false positives. Because IgG responses to Pgp3 353 are durable, age-seroprevalence curves and statistics estimated from them may 354 reflect historical transmission patterns and remain high despite low levels of infection 355 resulting from control measures or secular trends. Restricting analysis to younger 356 children (e.g., children born after discontinuing antibiotic MDA) or carefully 357 accounting for past MDA treatments in the interpretation of antibody data may 358 decrease false positives detected by IgG. 359

360

Here, we focused on IgG among young children and its relationship with C. 361 trachomatis infection to extend a previous study that combined nine trachoma 362 serology surveys and compared IgG seroconversion rates with clinical indicators 363 among people of all ages.⁴⁵ Limiting the analysis to young children rather than all 364 ages enabled us to simplify the modeling approach used to estimate seroconversion 365 rates under the assumption that transmission was approximately stable over the age 366 range. We focused on the relationship between serology and PCR infection to 367 assess the utility of serology to monitor differences in pathogen transmission. 368 369

The threshold analyses show that Pgp3 serology provides good overall 370 discrimination of the presence of C. trachomatis infections in a community 371 (AUC=0.92), even when limited to children 1 to 5 years old, but there are two 372 caveats to the generalizability of the thresholds estimated in this analysis. First, we 373 used clusters as the unit of analysis — a much finer spatial scale than the current 374 scale of decision making for elimination programs, which is typically at the 375 administrative district-level. We felt a similar, non-parametric threshold analysis at 376 the district (study) level would not be informative with only 11 studies that included 377 C. trachomatis infection measurements (Fig. 1), versus 281 unique clusters (Fig. 6). 378 Yet, the small number of children in any single cluster (median = 40) means that rare 379 infections could be missed without a larger sample size as populations approach 380 elimination (for example, if true C. trachomatis prevalence were 1%, then n = 300381 children would need to be tested to have a 95% probability of detecting at least one 382 C. trachomatis infection, assuming perfect test sensitivity and independent tests, 383 where $1 - [1 - P(Ct^+)]^n \ge 0.95$). It would be rare to encounter 300 young children in 384 a single sampling cluster, so averaging over a larger spatial scale or over repeated 385 surveys in the same clusters could improve the robustness of C. trachomatis 386 infections as a gold standard against which serology is compared. A second caveat 387 is that the analysis included the full range of transmission settings, and lower 388 thresholds may be needed to best discriminate in low transmission settings (similar 389 to Malawi or Kongwa 2018 populations, Fig. 6). Building from these promising 390 results, in future work our team plans to assess serology thresholds at the district-391 level with a focus on near-elimination and post-elimination settings. 392

393

This work is subject to limitations. First, the data we analyzed were compiled from 394 different previously published studies and sites that were available to us. Our results 395 may not be representative of all populations with ongoing trachoma transmission. 396 For example, the included studies come from five countries in Africa, but trachoma 397 continues to be endemic in the other regions of Africa, Latin America, Asia, and the 398 Pacific Islands.⁴⁸ As a secondary analysis, our work was also affected by design 399 features of individual studies, such as site selection in RCTs, which were typically 400 not selected using probability samples. Second, all models used to estimate 401 seroconversion, except for the semiparametric spline model, assumed homogeneity 402 of seroconversion rate over age and time. For most studies, we expected stable 403 transmission among 1–9-year-olds in the recent past. Our analysis used an estimate 404 of seroreversion from one longitudinal cohort,⁴⁹ but data beyond this cohort is limited 405 and seroreversion may be lower in higher transmission settings.⁵⁰ In a sensitivity 406 analysis no single seroreversion value resulted in the best model fit across 407 408 populations (Supplementary Fig. 8). Finally, we were unable to evaluate more specific subgroups, such as populations with different MDA histories or populations 409 experiencing recrudescence, due to limited data. Based on the variability observed 410 between populations, refinement of thresholds may be warranted as more data are 411 collected. 412

In conclusion, IgG responses to *C. trachomatis* antigen Pgp3 among 1–9-year-olds 414 aligned closely with ongoing transmission as measured by PCR and TF across a 415 range of trachoma endemicity settings. Consistent with patterns observed across 416 other pathogens, age-dependent Pgp3 seroprevalence curves became flatter and 417 seroconversion rates declined to zero as populations approached elimination -418 providing a coherent framework for monitoring *C. trachomatis* transmission in 419 seroepidemiologic studies. Serologic summaries estimated via a range of model 420 complexity were sensitive markers of ocular chlamydial infection and were consistent 421 with one another, implying that simpler approaches are likely sufficient to capture 422 variation in transmission. These results support use of serologic surveys to inform 423 trachoma programs as populations approach and achieve elimination. 424

425

Methods 426

Contributing studies 427

We gathered data from published trachoma serology surveys, with an emphasis on 428 IgG antibody responses to Pgp3 collected among children aged 1-9 years and 429 relatively recent reports (Supplementary Table 1). All studies were conducted 430 between 2012 and 2019. Children below the age of 1 year were excluded to mitigate 431 the influence of maternal antibodies. Based on the original study designs, 432 measurements in Matameye, Niger (PRET) and Wag Hemra, Ethiopia (TAITU) were 433 restricted to children aged under 6 years; in Dosso, Niger (MORDOR), the study was 434 limited to children aged under 5 years; and in Alefa, Andabet, Dera, and Woreta 435 town. Ethiopia, infections were measured among children aged 1-5-years, while 436 serology and TF were measured among children aged 1-9-years. For 437 measurements collected as part of a population-based surveys, multi-level cluster 438 random sampling was used. For measurements collected as part of a randomized 439 controlled trial, we combined data across arms unless otherwise noted (e.g., 440 stratification by recent MDA). Due to changing transmission and/or control 441 interventions in studies with repeated cross-sectional data (WUHA in Wag Hemra, 442 Ethiopia; Kongwa, Tanzania from 2012-2015; MORDOR in Dosso, Niger), we 443 included only the most recent year of measurements with serology, and PCR 444 measurements if available, for each population. We excluded clusters with fewer 445 than 15 children measured to ensure sufficient information to estimate cluster level 446 means (n=22 clusters excluded, reduced from 481 to 459). Measurement sample 447 sizes reflect distinct samples from individual children. 448

449

Details of serologic, clinical, and PCR measurements can be found in the published 450 reports for each study.^{26–38} In Malawi, dried blood spots were tested for IgG 451 antibodies against Pgp3 using ELISA. Samples were added to Immulon 2HB plates 452 (Southern Biotech, Birmingham, AL, USA) pre-sensitized with Pgp3 protein and 453 incubated for two hours. After 4 washes, plates were incubated with anti-human IgG-454 HRP (Southern Biotech) for 1 hour. Plates were then washed and incubated with 455 3,3',5,5'-tetramethylbenzidine (KPL, Gaithersburg, MD, USA). The reaction was 456

stopped with 1N H2SO4 and plates were read at 450 nm on a microplate reader. 457 The seropositivity cutoff was determined based on a finite mixture model.³¹ ELISA-458 based population-level measurements of Pgp3 have been shown to have good 459 agreement with multiplex bead assays.⁵¹ 460

461

In all other included studies, dried blood spots were analyzed for IgG antibodies to 462 Pgp3 using a multiplex bead assay on a Luminex platform. Briefly, Pgp3-coupled 463 beads were incubated with diluted sample for 1.5 hours, washed, and then incubated 464 with anti-human IgG (Southern Biotech, Birmingham, AL, USA) and anti-human IgG4 465 (Southern Biotech) for 45 minutes. After additional washes, beads were incubated 466 with phycoerythrin-labeled streptavidin (Invitrogen, Waltham, MA, USA) for 30 467 minutes, washed, and then incubated with phosphate buffered saline (PBS) 468 containing 0.5% BSA, 0.05% Tween-20 and 0.02% sodium azide. After a final wash, 469 beads were resuspended in 1X PBS and read on a Bio-Plex 200 instrument (Bio-470 Rad, Hercules, CA). IgG levels were reported as median fluorescence intensity 471 minus background (MFI-bg), and seropositivity cutoffs were generated using receiver 472 operator characteristic (ROC) methods.¹⁴ We used MFI-bg cutoffs defined by each 473 study to assign seropositivity status. The MFI-bg cutoffs can vary slightly by study 474 due to differences in antigen-bead coupling efficiency in different bead sets, and 475 ranged from 882 (Kongwa, Tanzania 2013) to 1771 (Kongwa, Tanzania 2018), with 476 a median of 1558 (Alefa, Andabet, Dera, and Woreta town, Ethiopia 2017). De-477 identified Source data provided with this study include the cutoffs used for each bead 478 set. To assess robustness to seropositivity cutoffs, we compared seroprevalence 479 and seroconversion rate calculated across a range of arbitrary cutoffs for four study 480 populations at different levels of trachoma prevalence (Supplementary Fig. 7), 481 which illustrate that the range over which cutoffs vary are unlikely to have a major 482 influence on seroprevalence or seroconversion rate estimates. 483

484

Clinical disease was assessed by trained field graders according to the WHO 485 simplified grading system,⁵² which defines TF as the presence of five or more 486 follicles which are (a) at least 0.5 mm in diameter and (b) located in the central part 487 of the upper tarsal conjunctiva. Conjunctival swabs were assessed for C. 488 trachomatis DNA using PCR. In five out of seven studies with PCR measurements, 489 cluster-level prevalence was estimated from individual-level results.^{29–31,35,36} In one 490 study (PRET), cluster-level prevalence was estimated from pooled results using 491 maximum likelihood methods.^{26,53} For Andabet, Dera, Woreta town, and Alefa, 492 Ethiopia, C. trachomatis infection prevalence was estimated at the district level from 493 pooled results using maximum likelihood methods.²⁸ 494

495

Cluster-level prevalence was calculated as the number of children who were sero-, 496 PCR- or TF-positive divided by the number of children tested for the respective 497 outcome. When possible, "populations" were defined by districts or evaluation units 498 currently used for trachoma monitoring. Population-level prevalence estimates were 499 500 defined as the median value across clusters. Age-seroprevalence curves were

estimated by pooling all measurements at the population level, calculating 501

seroprevalence for one-year age groups, and fitting cubic spline models to generate 502 smooth trend lines. 503

504

Estimating serology-based summary measures 505

We summarized IgG responses as geometric mean IgG levels, seroprevalence, and 506 seroconversion rates from several models. The seroconversion rate from a current 507 status, single-rate catalytic model assuming no seroreversion is closely tied to the 508 slope of age-seroprevalence curve.⁵⁴ Specifically, the hazard (seroconversion rate) is 509 equal to the slope of the age-seroprevalence curve divided by the complement of the 510 seroprevalence at age A=a. It can be shown that the seroconversion rate based on 511 this model can be estimated as the exponentiated intercept from a generalized linear 512 model with binomial error structure and a complementary log-log link: ⁵⁵ 513

- 514
- 515
- 516

$$\log\left[-\log(1 - P(Y = 1 \mid A))\right] = \log(\lambda) + \log(A) \tag{1}$$

where Y represents individual level serostatus (1: seropositive, 0: seronegative or 517 equivocal), A is the child's age in years, and λ is the seroconversion rate. The 518 seroconversion rate provides an estimate of the force of infection, an epidemiological 519 parameter that denotes the rate at which susceptible individuals in the population 520 become infected. 521

522

Next, we extended this model to allow for seroreversion. Cross-sectional data do not 523 contain sufficient information to reliably estimate both seroreversion and 524 seroconversion rates.⁵⁶ Therefore, we fit a binomial maximum likelihood model for 525 seroconversion with fixed seroreversion rates ranging from 0.02 to 0.20 per person-526 year:22,45 527

528

$$(Y = 1 | A) = \frac{\lambda}{\lambda + \rho} [1 - \exp(-(\lambda + \rho) \times A)]$$
(2)

529

P(

530 where ρ is the assumed seroreversion rate. In our main analyses, we assumed a seroreversion rate of 6.6 per 100 person-years based on a longitudinal cohort in 531 Kongwa, Tanzania monitored in the absence of MDA,⁴⁹ which is likely conservative 532 for higher transmission settings.⁵⁰ No level of seroreversion consistently provided the 533 best fit across populations (Supplementary Fig. 8). This model did not converge in 534 several clusters (6 out of 416 clusters with seroprevalence >0%, or 1.4%), which 535 often contained few seropositive children. 536

537

Finally, we fit semiparametric models to allow seroconversion to vary by age.⁵⁴ We fit 538 539 semiparametric models only at the population level, as they require more data than are typically available at the sampling cluster level (around 20-40 children). We fit a 540 generalized linear model with complementary log-log link for seropositivity: 541

$$\log[-\log(1 - P(Y = 1 | A))] = g(A)$$
(3)

where g(A) is a flexible function for age modeled using cubic splines. To estimate the average seroconversion rate in each population, λ , we integrated over age using predictions from the model. We used the relationship between the hazard $\lambda(a)$ and cumulative incidence F(a), where F(a) is the predicted seroprevalence at age a(details in ⁴²).

549

$$\lambda = \int_{a_1}^{a_2} \lambda(a) da = \frac{\log[1 - F(a_1)] - \log[1 - F(a_2)]}{a_2 - a_1}$$
(4)

550

551 Comparison of different trachoma indicators

We used the Pearson correlation coefficient to compare serologic summaries and TF 552 prevalence with PCR prevalence at the population and cluster levels. We conducted 553 this analysis across all populations with PCR measurements and explored the 554 impact of contextual factors by stratifying clusters into subgroups defined by MDA in 555 the past year (yes / no) and age range (1–9-year-olds / 1–5-year-olds). We 556 estimated asymptotic 95% confidence intervals for study-level correlation using 557 558 Fisher's Z transform. To estimate 95% confidence intervals for cluster level correlation estimates we used a non-parametric bootstrap (1,000 replicates) that 559 resampled clusters with replacement, stratified by study. 560

561

We used the Spearman rank correlation coefficient to compare different serologic summaries with one another at the cluster level, allowing for non-linearity in the relationships. We estimated simultaneous confidence intervals from a cubic spline to summarize the relationship between markers at the cluster level, including a random effect for study to allow for correlated measures within-study.

567

568 Serologic thresholds for elimination

We used a non-parametric approach to assess thresholds of seroprevalence or 569 seroconversion rates to classify clusters without PCR infections. For overall 570 estimates, we combined clusters from all populations with PCR measurements, for a 571 total of 281 clusters and 112 clusters with at least one PCR-detected infection. We 572 defined a range of cutoffs covering nearly all cluster-level estimates (0 to 100% for 573 seroprevalence, 0 to 50 per 100 person-years for seroconversion rate) and divided 574 the range into 200 increments. At each step, we calculated sensitivity as the 575 proportion of clusters with serology values above the threshold among clusters with 576 any infection, and specificity as the proportion of clusters with serology value less 577 than or equal to the threshold among clusters with zero infections detected. We 578 identified the highest thresholds achieving at least 90% and 80% sensitivity. We also 579 presented these results as receiver operating characteristic (ROC) curves and 580 calculated overall area-under-the-curve (AUC). We calculated sensitivity, specificity, 581 and the ROC curve for each population separately. 582

583

584 Ethics and inclusion

585 The secondary analysis protocol was reviewed and approved by the Institutional

586 Review Board at the University of California, San Francisco (Protocol #20-33198).

All primary data that contributed to the analysis was collected after obtaining 587 informed consent from all participants or their guardians under separate, local 588 human subjects research protocols in accordance with the Declaration of Helsinki. 589 Members from each contributing primary research study have participated as 590 collaborators and co-authors on the present analyses from their initial stages, 591 including the design, interpretation, and summary of results. Co-authors were 592 nominated by each study's principal investigator to represent the country and study 593 teams that originally contributed the data. De-identified datasets made public 594 through this analysis have been reviewed and approved by representatives from 595 each study and conform with ethical guidelines set forth in the original protocols. 596 Analyses were led by investigators at the University of California, San Francisco with 597 guidance and input from all co-authors to incorporate local stakeholder perspectives. 598 599

600 Data Availability

601 De-identified data to reproduce this work are publicly available without restriction in 602 the Open Science Framework repository, <u>https://osf.io/e6j5a/</u>.⁵⁷ Processed, de-603 identified data generated in this study are additionally provided in the Supplementary 604 Information/Source Data file.

606 Code Availability

607 R version 4.2.2 (2022-10-21, "Innocent and Trusting") was used for this analysis.⁵⁸ 608 Open source code and instructions to reproduce all analyses are available in the

- 609 Open Science Framework repository, <u>https://osf.io/e6j5a/</u>.⁵⁷
- 610

- 611
- 612

613 **References**

- World Health Organization. Ending the neglect to attain the sustainable development
 goals: a roadmap for neglected tropical diseases 2021-2030.
 https://apps.who.int/iris/handle/10665/361856 (2020).
- 617 2. Taylor, H. R., Burton, M. J., Haddad, D., West, S. & Wright, H. Trachoma. *The Lancet*618 384, 2142–2152 (2014).
- Keenan, J. D. *et al.* Clinical Activity and Polymerase Chain Reaction Evidence of
 Chlamydial Infection after Repeated Mass Antibiotic Treatments for Trachoma. *Am. J. Trop. Med. Hyg.* 82, 482–487 (2010).
- Amza, A. *et al.* Community-level Association between Clinical Trachoma and Ocular
 Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of
 Niger. *Ophthalmic Epidemiol.* 26, 231–237 (2019).
- 5. Ramadhani, A. M., Derrick, T., Macleod, D., Holland, M. J. & Burton, M. J. The
 Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection
 before and after Mass Antibiotic Treatment. *PLoS Negl. Trop. Dis.* **10**, e0005080 (2016).
- 6. Assaad, F. A. & Maxwell-Lyons, F. Systematic observer variation in trachoma studies. *Bull. World Health Organ.* 36, 885–900 (1967).
- 7. Tielsch, J. M. *et al.* Trachoma grading: observer trials conducted in southern Malawi. *Br. J. Ophthalmol.* **71**, 371–374 (1987).
- 632 8. Gebresillasie, S. *et al.* Inter-Rater Agreement between Trachoma Graders: Comparison
 633 of Grades Given in Field Conditions versus Grades from Photographic Review.
 634 *Ophthalmic Epidemiol.* 22, 162–169 (2015).
- 635 9. Corran, P., Coleman, P., Riley, E. & Drakeley, C. Serology: a robust indicator of malaria
 636 transmission intensity? *Trends Parasitol.* 23, 575–582 (2007).
- 637 10. Stringhini, S. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva,
 638 Switzerland (SEROCoV-POP): a population-based study. *Lancet Lond. Engl.* **396**, 313–
 639 319 (2020).
- 11. Woodhall, S. C. *et al.* Advancing the public health applications of Chlamydia trachomatis
 serology. *Lancet Infect. Dis.* **18**, e399–e407 (2018).
- Martin, D. L. *et al.* The use of serology for trachoma surveillance: Current status and
 priorities for future investigation. *PLoS Negl. Trop. Dis.* **14**, e0008316 (2020).
- 644 13. Cooley, G. M. *et al.* No Serological Evidence of Trachoma or Yaws Among Residents of
 645 Registered Camps and Makeshift Settlements in Cox's Bazar, Bangladesh. *Am. J. Trop.*646 *Med. Hyg.* **104**, 2031–2037 (2021).
- 647 14. Goodhew, E. B. *et al.* CT694 and pgp3 as Serological Tools for Monitoring Trachoma
 648 Programs. *PLoS Negl. Trop. Dis.* 6, e1873 (2012).
- 649 15. Goodhew, E. B. *et al.* Longitudinal analysis of antibody responses to trachoma antigens
 650 before and after mass drug administration. *BMC Infect. Dis.* 14, 3154 (2014).
- 16. Gwyn, S. *et al.* Comparison of Platforms for Testing Antibody Responses against the
 Chlamydia trachomatis Antigen Pgp3. *Am. J. Trop. Med. Hyg.* **97**, 1662–1668 (2017).
- Miegand, R. E. *et al.* Latent class modeling to compare testing platforms for detection of
 antibodies against the Chlamydia trachomatis antigen Pgp3. *Sci. Rep.* 8, 4232 (2018).
- 18. Goodhew, B. *et al.* Validation of immunoassays for the Chlamydia trachomatis antigen
 Pgp3 using a chimeric monoclonal antibody. *Sci. Rep.* **13**, 7281 (2023).
- 19. Migchelsen, S. J. et al. Defining Seropositivity Thresholds for Use in Trachoma
- Elimination Studies. *PLoS Negl. Trop. Dis.* **11**, e0005230 (2017).

Kaur, H., Dize, L., Munoz, B., Gaydos, C. & West, S. K. Evaluation of the reproducibility
 of a serological test for antibodies to Chlamydia trachomatis pgp3: A potential

surveillance tool for trachoma programs. *J. Microbiol. Methods* **147**, 56–58 (2018).

- 21. Wang, J. *et al.* A Genome-Wide Profiling of the Humoral Immune Response to
 Chlamydia trachomatis Infection Reveals Vaccine Candidate Antigens Expressed in
 Humans. *J. Immunol.* **185**, 1670–1680 (2010).
- Martin, D. L. *et al.* Serology for Trachoma Surveillance after Cessation of Mass Drug
 Administration. *PLoS Negl. Trop. Dis.* 9, e0003555 (2015).
- 23. Pant, B. P. *et al.* Control of Trachoma from Achham District, Nepal: A Cross-Sectional
 Study from the Nepal National Trachoma Program. *PLoS Negl. Trop. Dis.* **10**, e0004462
 (2016).
- West, S. K. *et al.* Can We Use Antibodies to Chlamydia trachomatis as a Surveillance
 Tool for National Trachoma Control Programs? Results from a District Survey. *PLoS Negl. Trop. Dis.* **10**, e0004352 (2016).
- 673 25. Arnold, B. F., Scobie, H. M., Priest, J. W. & Lammie, P. J. Integrated Serologic
 674 Surveillance of Population Immunity and Disease Transmission. *Emerg. Infect. Dis.* 24,
 675 1188–1194 (2018).
- 26. Amza, A. *et al.* A Cluster-Randomized Trial to Assess the Efficacy of Targeting
 Trachoma Treatment to Children. *Clin. Infect. Dis.* 64, 743–750 (2017).
- Kim, J. S. *et al.* Community-level chlamydial serology for assessing trachoma elimination
 in trachoma-endemic Niger. *PLoS Negl. Trop. Dis.* **13**, e0007127 (2019).
- 28. Nash, S. D. *et al.* Population-Based Prevalence of Chlamydia trachomatis Infection and
 Antibodies in Four Districts with Varying Levels of Trachoma Endemicity in Amhara,
 Ethiopia. *Am. J. Trop. Med. Hyg.* **104**, 207–215 (2021).
- 683 29. Wilson, N. *et al.* Evaluation of a Single Dose of Azithromycin for Trachoma in Low-684 Prevalence Communities. *Ophthalmic Epidemiol.* **26**, 1–6 (2019).
- 30. Odonkor, M. *et al.* Serology, infection, and clinical trachoma as tools in prevalence
 surveys for re-emergence of trachoma in a formerly hyperendemic district. *PLoS Negl. Trop. Dis.* **15**, e0009343 (2021).
- Burr, S. E. *et al.* Pgp3 seroprevalence and associations with active trachoma and ocular
 Chlamydia trachomatis infection in Malawi: cross-sectional surveys in six evaluation
 units. *PLoS Negl. Trop. Dis.* **13**, e0007749 (2019).
- 32. Hammou, J. *et al.* Post-Validation Survey in Two Districts of Morocco after the
 Elimination of Trachoma as a Public Health Problem. *Am. J. Trop. Med. Hyg.* 106,
 1370–1378 (2022).
- 33. Hammou, J. *et al.* In Morocco, the elimination of trachoma as a public health problem
 becomes a reality. *Lancet Glob. Health* 5, e250–e251 (2017).
- 34. Wittberg, D. M. *et al.* WASH Upgrades for Health in Amhara (WUHA): study protocol for
 a cluster-randomised trial in Ethiopia. *BMJ Open* **11**, e039529 (2021).
- Melo, J. S. *et al.* Targeted Antibiotics for Trachoma: A Cluster-Randomized Trial. *Clin. Infect. Dis.* **73**, 979–986 (2021).
- 36. Aragie, S. *et al.* Water, sanitation, and hygiene for control of trachoma in Ethiopia
 (WUHA): a two-arm, parallel-group, cluster-randomised trial. *Lancet Glob. Health* **10**,
 e87–e95 (2022).
- 37. Arzika, A. M. *et al.* Effect of biannual azithromycin distribution on antibody responses to
 malaria, bacterial, and protozoan pathogens in Niger. *Nat. Commun.* **13**, 976 (2022).

- 38. Arzika, A. M. *et al.* Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged
 Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial. *JAMA Netw. Open* 5, e2228244 (2022).
- 39. Solomon, A. W. *et al.* Trachoma. *Nat. Rev. Dis. Primer* **8**, 1–20 (2022).
- 40. Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases,
 malaria, and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.*11, e0005616 (2017).
- 41. Tedijanto, C. *et al.* Predicting future community-level ocular Chlamydia trachomatis
 infection prevalence using serological, clinical, molecular, and geospatial data. *PLoS Negl. Trop. Dis.* **16**, e0010273 (2022).
- 42. Arnold, B. F. *et al.* Fine-scale heterogeneity in *Schistosoma mansoni* force of infection
 measured through antibody response. *Proc. Natl. Acad. Sci.* **117**, 23174–23181 (2020).
- 43. Amoah, B. *et al.* Model-based geostatistics enables more precise estimates of neglected
 tropical-disease prevalence in elimination settings: mapping trachoma prevalence in
 Ethiopia. *Int. J. Epidemiol.* 51, 468–478 (2022).
- 44. Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases,
 malaria, and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.*11, e0005616 (2017).
- 45. Pinsent, A. *et al.* The utility of serology for elimination surveillance of trachoma. *Nat. Commun.* 9, 5444 (2018).
- 46. Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance of
 malaria transmission intensity. *Sci. Rep.* 6, 19472 (2016).
- 47. Sepúlveda, N., Stresman, G., White, M. T. & Drakeley, C. J. Current Mathematical
 Models for Analyzing Anti-Malarial Antibody Data with an Eye to Malaria Elimination and
 Eradication. *J. Immunol. Res.* 2015, 1–21 (2015).
- 48. Renneker, K. K. *et al.* Global progress toward the elimination of active trachoma: an analysis of 38 countries. *Lancet Glob. Health* **10**, e491–e500 (2022).
- 49. West, S. K. *et al.* Longitudinal change in the serology of antibodies to Chlamydia
 trachomatis pgp3 in children residing in a trachoma area. *Sci. Rep.* **8**, 3520 (2018).
- 50. Tedijanto, C. *et al.* Seroreversion to Chlamydia trachomatis Pgp3 antigen among young
 children in a hyperendemic region of Amhara, Ethiopia. *MedRxiv Prepr.*2023.02.04.23285360 (2023) doi:10.1101/2023.02.04.23285360.
- 51. Gwyn, S. *et al.* The Performance of Immunoassays to Measure Antibodies to the
 Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for
 Trachoma. *Am. J. Trop. Med. Hyg.* (2021) doi:10.4269/ajtmh.21-0541.
- 52. Thylefors, B., Dawson, C. R., Jones, B. R., West, S. K. & Taylor, H. R. A simple system
 for the assessment of trachoma and its complications. *Bull. World Health Organ.* 65,
 477–483 (1987).
- 53. Ray, K. J. *et al.* Estimating Community Prevalence of Ocular *Chlamydia trachomatis*Infection using Pooled Polymerase Chain Reaction Testing. *Ophthalmic Epidemiol.* 21, 86–91 (2014).
- 54. Hens, N., Shkedy, Z., Aerts, M., Damme, C. F. P. V. & Beutels, P. *Modeling Infectious Disease Parameters Based on Serological and Social Contact Data*. (Springer, 2012).
- 55. Jewell, N. P. & Laan, M. V. Generalizations of current status data with applications.
 Lifetime Data Anal. 1, 101–109 (1995).
- 56. Arnold, B. F. *et al.* Enteropathogen antibody dynamics and force of infection among
 children in low-resource settings. *eLife* 8, e45594 (2019).

- 57. Arnold, B. F. & Tedijanto, C. Monitoring transmission intensity of trachoma with serology:
 source data and code. (2023) doi:10.17605/OSF.IO/E6J5A.
- 58. R Core Team. *R: A language and environment for statistical computing.* (R Foundation
 for Statistical Computing, 2020).
- 756 757

758 Acknowledgements

Funding statement. This work was supported by the National Institute of Allergy andInfectious Diseases (R01-Al158884 to B.F.A.).

761

Disclaimer. The findings and conclusions in this article are those of the authors and
 do not necessarily represent the official position of the National Institutes of Health or
 the Centers for Disease Control and Prevention. Use of trade names is for
 identification only and does not imply endorsement by the Public Health Service or

- by the U.S. Department of Health and Human Services. The authors alone are
- responsible for the views expressed in this article, and they do not necessarily
- represent the views, decisions, or policies of the institutions with which they are
- affiliated. AWS is a staff member of the World Health Organization.
- 770

771 Author Contributions

- Following <u>CRediT taxonomy</u>: conceptualization (CT, AWS, DLM, SDN, PJL, BFA),
- data curation (CT, DLM, BFA), formal analysis (CT, BFA), funding acquisition (BFA,
- DLM), investigation (CT, BFA), methodology (CT, BFA), project administration (DLM,
- BFA), resources (all authors), software (CT, BFA), supervision (AWS, DLM, SDN,
- SKW, TML, JDK, PJL), validation (CT, BG, DLM, BFA), visualization (CT, BFA),
- writing original draft preparation (CT, BFA), writing review & editing (all authors)
- 778

779 Competing Interests

- 780 The authors declare no competing interests.
- 781

782



* Estimates collected in population based survey † Serology, PCR, and TF measured among 1-5 year olds only

‡ PCR prevalence measured only at the district-level among 1-5 year olds

783 784

Figure 1. Seroprevalence, PCR positivity, and TF prevalence across study populations. 785 Cluster-level prevalence estimates are represented by colored lines, and overlaid boxplots 786 show the median, interguartile range, and range (excluding outliers defined as points more 787 than 1.5 times the interguartile range from the 25th or 75th percentile) for each population. 788 789 Study site, country, study name (if applicable), and year of data collection are listed on the left with number of individuals (n) and number of clusters (m) included in the analyses. For studies 790 with only district-level estimates of PCR prevalence the mean is indicated with a circle rather 791 than box plot. NA marks studies that did not measure PCR or trachomatous inflammation— 792 follicular (TF). Study populations are arranged in descending order of seroconversion rates, 793 presented in Figure 2. Source data are provided with this paper. Created with notebook 794 https://osf.io/gjst8. 795





Figure 2. Age-dependent seroprevalence curves, modeled seroconversion rates, and 798 **PCR prevalence across study populations.** Cubic splines fit to seroprevalence by age are 799 shown in the left plot. Cluster-level seroconversion rates and PCR prevalence estimates are 800 represented by colored lines, and overlaid boxplots show the median, interquartile range, and 801 range (excluding outliers defined as points more than 1.5 times the interguartile range from 802 the 25th or 75th percentile) for each population. Figure 1 includes each study's sample size. 803 Study populations are arranged in descending order of median seroconversion rate assuming 804 no seroreversion. C. trachomatis PCR measurements are identical to Figure 1 and are 805 included for reference. For studies with only district-level estimates of PCR prevalence, the 806 mean is indicated with a circle rather than box plot. NA indicates that a study did not measure 807 C. trachomatis infections with PCR. Abbreviations: PY = person-years; ETH = Ethiopia; MAR 808 = Morocco; MWI = Malawi; NER = Niger; TZA = Tanzania. Source data are provided with this 809 paper. Created with notebook https://osf.io/rghyc. 810

- 811
- 812





814

816 Figure 3. Relationship between different cluster-level serologic summary measures. a 817 Geometric mean IgG response versus seroprevalence. b Seroconversion rate versus 818 seroprevalence. c Seroconversion rate allowing for seroreversion versus a seroconversion 819 rate that assumes no seroreversion. d Seroconversion rate that assumes seroreversion 820 821 versus seroprevalence. Spearman rank correlations across sampling clusters are shown for 822 each comparison. In all panels, small points represent cluster-level estimates and medians for each study population are represented by larger points with black outline. Shaded bands 823 824 show simultaneous 95% confidence intervals for a spline fit through cluster-level estimates. A 825 fixed seroreversion rate of 6.6 per 100 person-years was assumed in the catalytic model allowing for seroreversion (Methods). Figure 1 includes each study's sample size (median 826 827 cluster size = 40 children). Abbreviations: PY = person-years; ETH = Ethiopia; MAR = Morocco; MWI = Malawi; NER = Niger; TZA = Tanzania. Source data are provided with this 828 paper. Created with notebook https://osf.io/wcv86. 829 830





832 833

Figure 4. Relationship between trachoma biomarkers in the presence and absence of 834 recent mass distribution of azithromycin (MDA). a Correlations between cluster PCR 835 prevalence and seroprevalence overall and stratified by whether the study population had 836 received MDA in the previous year. b Correlations between PCR prevalence and TF 837 prevalence overall and stratified by whether the study population had received MDA in the 838 previous year. In all panels, medians across clusters for each study population are 839 840 represented by larger points with black outline. Each plot includes the identity line (dotted) and 841 Pearson correlations at the cluster- and population-levels. 95% confidence intervals (CIs) are based on 1,000 bootstrapped samples, holding populations fixed and resampling clusters with 842 replacement. Population-level estimates are included for Andabet, Dera, Woreta town, and 843 Alefa, Ethiopia, but cluster-level PCR prevalence was not available for these populations. 844 845 Figure 1 includes each study's sample size. Abbreviations: ETH = Ethiopia; MWI = Malawi; NER = Niger; TZA = Tanzania. Source data are provided with this paper. Created with 846 notebook https://osf.io/rt825. 847





850 851

Figure 5. Relationship between trachoma biomarkers in different monitoring age 852 ranges. a Correlations between cluster PCR prevalence and seroprevalence overall and 853 stratified by age of monitoring population. b Correlations between C. trachomatis PCR 854 prevalence and TF prevalence overall and stratified by age of monitoring population. In all 855 panels, medians across clusters for each study population are represented by larger points 856 with black outline. Each plot includes the identity line (dotted) and Pearson correlations at the 857 858 cluster- and population-levels. 95% confidence intervals (CIs) are based on 1,000 bootstrapped samples, holding populations fixed and resampling clusters with replacement. 859 Population-level estimates are included for Andabet, Dera, Woreta town, and Alefa, Ethiopia, 860 but cluster-level PCR prevalence was not available for these populations. Figure 1 includes 861 each study's sample size. Abbreviations: ETH = Ethiopia; MWI = Malawi; NER = Niger; TZA 862 = Tanzania; TF = trachomatous inflammation—follicular. Source data are provided with this 863 paper. Created with notebook https://osf.io/rt825 . 864



867 868

Figure 6. Identification of clusters with C. trachomatis infection using seroprevalence. 869 a Sensitivity and specificity curves for identification of clusters with any C. trachomatis PCR 870 infections based on different seroprevalence thresholds among children 1-9 years old (n = 871 872 281 clusters, 112 clusters with PCR>0%). Vertical lines delineate sensitivity at 90% (solid line, 13.5% seroprevalence) and 80% (dotted line, 22.5% seroprevalence). Thin lines show 873 sensitivity for each study population with cluster-level PCR measurements. Points at the 874 875 bottom of the panel mark seroprevalence estimates for each study population. b Receiver 876 operating characteristic (ROC) curves for all clusters (thick black line) and for each study 877 population (thin colored lines) with overall area-under-the-curve (AUC). Note that the ROC 878 curve for Kongwa, TZA 2013 lies beneath the curve for Wag Hemra, ETH (WUHA). Figure 1 includes each study's sample size. Abbreviations: ETH = Ethiopia; MWI = Malawi; NER = 879 Niger; TZA = Tanzania. Supplementary Data 1 includes underlying sensitivity and specificity 880 values at each cutoff. Source data are provided with this paper. Created with notebook 881 https://osf.io/vgekh . 882